Prograf Class Cert. Makes Case Unworkable, 1st Circ. Hears

By Jacqueline Bell (October 5, 2015, 9:01 PM EDT) -- Astellas Pharma US LLC pressed the First Circuit Monday to nix a ruling certifying a class of indirect purchasers who claim the drugmaker improperly delayed generic competition for the immunosuppressant drug Prograf, arguing it would be an impossible task to weed out the class members who can't actually prove they were injured....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!